Poonawalla noted that reducing the timeframe would give "real relief" to the people who want to travel abroad.
The Covid-19 vaccine demonstrated an overall 90.4 per cent efficacy in phase 3 clinical trials, reports Sohini Das
'The challenge will be making sure its efficacy is high.' 'If a vaccine is only 50 to 60 per cent efficient, it's a double-edged sword.'
'SII has started stockpiling the vaccine and now has roughly 40 million doses ready. It is using some of the capacities it had for under development products for the COVID-19 vaccine and by January we will have a capacity to make 100 million doses per month and a stockpile of 200 million doses.'
The Pune-based company's chief executive Adar Poonawalla said the company, which is the largest vaccine maker in the world, is putting $200 million at risk by manufacturing nearly 300 million doses before the final nod to launch the vaccine in market, which is expected at best by the end of the year.
There are a number of trial sites across both Mumbai and Pune that we have shortlisted, as these cities have many hotspots, which will help us understand the efficacy of the vaccine, the company's chief executive Adar Poonawalla said.
Businessmen from all over the world attended Radhika Merchant and Anant Ambani's wedding at the Jio World Convention Centre, Bandra Kurla Complex, north west Mumbai, on Friday, July 12, 2024.
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.
The Indian Council of Medical Research was in talks with the Serum Institute of India for local manufacturing of monoclonal antibodies (MABs). However, it did not take off, as the volume was much less in India.
Siddharth Roy Kapur's RKF aims to raise around $50 million by offering up to a 50 per cent stake in the company.
The world is learning about a side effect of the COVID vaccine called Thrombosis with Thrombocytopenia Syndrome, he said.
Recouping the dent caused by the Hindenburg Research report, Gautam Adani's networth shot up 95 per cent to Rs 11.6 lakh crore last year, which helped him replace Mukesh Ambani to become the richest Indian, a report said on Thursday. Reliance Industries chairman and managing director Ambani's overall networth increased by 25 per cent to Rs 10.14 lakh crore, as per the 2024 Hurun India Rich List. In 2023's report, Adani's wealth declined by 57 per cent to Rs 4.74 lakh crore, and Ambani was way ahead with a fortune of Rs 8.08 lakh crore.
Pharma giant AstraZeneca's Covid-19 vaccine is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British newspaper The Telegraph.
'What is Balaji without Ekta (Kapoor), what is Dharma without Karan (Johar?)'
Industry experts believe that this deal will positively impact the Indian film industry, which is struggling with fewer movie releases.
Serum Institute of India chief Adar Poonawalla will pay 138 million (about Rs 1,444 crore) for a Mayfair mansion in London in one of the city's most expensive home sales of the year
Business tycoons at the Ambani's pre-wedding celebrations at Jamnagar, Gujarat.
'I understand some people are comfortable getting a Covishield shot as their third dose.'
India currently does not have any XBB 1.5 variant-based vaccines available.
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is unknown, according to court papers being quoted in the UK media.
The Adani family, led by Chairman Gautam Adani, is the most valued first-generation family business at Rs 15.44 trillion.
Dengue has become a major public health concern in India with 289,235 cases reported last year. This year there were 19,447 cases of dengue which resulted in 19 deaths till April 2024.
This will also help test the effectiveness of preventing the entry of Nipah in target cells.
Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST.
Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.
Despite these rare occurrences, the pharmaceutical company maintains that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy.
'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'
Billionaire Mukesh Ambani's Reliance Industries and Tata Group have made it to the prestigious TIME's list of 100 World's Most Influential Companies of 2024. TIME called Reliance 'India's Juggernaut'. This is the second time that Reliance has found its way into the TIME list. Jio Platforms, the firm that holds digital properties of the conglomerate, was included in the inaugural TIME 100 Most Influential Companies List of 2021. Serum Institute is the other Indian company on the list.
It has been approved by the European Medicines Agency for conditional marketing authorisation.
'It is admitted that the AZ vaccine can, in very rare cases, cause TTS.'
India has covered enough population with vaccine and infection, but protein vaccines should remain available on payment basis for elderly and those with comorbidities.
Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively.
Actor Poonam Pandey is not being considered as the brand ambassador of the government's national campaign to spread awareness on cervical cancer, Union health ministry officials said on Wednesday.
An FIR was launched against some unidentified persons for cheating the SII for more than Rs 1 crore, said the officials on Sunday.
The development comes after requests for indemnity and exemption from bridging trials have been made by Pfizer and Moderna to the Indian government.
NCP president Sharad Pawar may be busy getting ready for the INDIA Opposition bloc meeting in Mumbai with other Maha Vikas Aghadi (MVA) constituents, but his close friend and industrialist Dr Cyrus Poonawalla has a piece of advice for the octogenarian leader.
Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.
'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'
The PM's visit would signal a strong intent towards making sure India becomes a beneficiary as vaccines become a massively traded commodity in the coming years.
We should be relieved that we got the doses but we must also know where they came from and who was and who was not responsible for this achievement, notes Aakar Patel.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances